EP1020434A4 — 3-amidinoaniline derivatives, activated blood coagulation factor x inhibitors, and intermediates for producing both
Assigned to Kissei Pharmaceutical Co Ltd · Expires 2000-11-15 · 26y expired
What this patent protects
3-Amidinoaniline derivatives represented by general formula (I) which have potent and selective activity of inhibiting activated blood coagulation factor X and are useful as activated blood coagulation factor X inhibitors, or pharmacologically acceptable salts thereof and interme…
USPTO Abstract
3-Amidinoaniline derivatives represented by general formula (I) which have potent and selective activity of inhibiting activated blood coagulation factor X and are useful as activated blood coagulation factor X inhibitors, or pharmacologically acceptable salts thereof and intermediates in producing the same, wherein R represents hydrogen, lower alkyl, lower alkenyl, etc; R1 represents hydrogen, hydroxy, lower alkyl, etc.; Y represents a single bond or oxygen; and R2 represents lower alkyl or a group represented by (a) wherein n is 1 or 2; and T is hydrogen or -C(=NH)-W (wherein W is lower alkyl).
Drugs covered by this patent
- Bevyxxa (BETRIXABAN) · Portola Pharms Inc
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.